Anchor Capital Advisors LLC Buys Shares of 10,847 Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Anchor Capital Advisors LLC purchased a new stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) in the fourth quarter, according to its most recent filing with the SEC. The firm purchased 10,847 shares of the biopharmaceutical company's stock, valued at approximately $7,727,000.

Other institutional investors have also modified their holdings of the company. State Street Corp boosted its position in Regeneron Pharmaceuticals by 1.3% during the third quarter. State Street Corp now owns 4,902,404 shares of the biopharmaceutical company's stock worth $5,153,603,000 after purchasing an additional 61,277 shares in the last quarter. Charles Schwab Investment Management Inc. raised its position in shares of Regeneron Pharmaceuticals by 1.7% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 673,261 shares of the biopharmaceutical company's stock worth $707,759,000 after purchasing an additional 11,499 shares during the last quarter. Swiss National Bank raised its stake in Regeneron Pharmaceuticals by 0.6% in the 3rd quarter. Swiss National Bank now owns 321,600 shares of the biopharmaceutical company's stock valued at $338,079,000 after purchasing an additional 2,000 shares during the last quarter. Sumitomo Mitsui Trust Group Inc. raised its stake in Regeneron Pharmaceuticals by 0.4% in the 4th quarter. Sumitomo Mitsui Trust Group Inc. now owns 302,616 shares of the biopharmaceutical company's stock valued at $215,562,000 after purchasing an additional 1,108 shares during the last quarter. Finally, National Pension Service raised its position in shares of Regeneron Pharmaceuticals by 4.0% in the fourth quarter. National Pension Service now owns 232,450 shares of the biopharmaceutical company's stock valued at $165,581,000 after buying an additional 8,833 shares during the last quarter. Hedge funds and other institutional investors own 83.31% of the company's stock.

Regeneron Pharmaceuticals Stock Performance

Shares of REGN stock traded down $12.50 on Monday, hitting $686.24. 120,512 shares of the stock traded hands, compared to its average volume of 601,677. The company's fifty day moving average is $698.51 and its 200 day moving average is $866.13. Regeneron Pharmaceuticals, Inc. has a 1-year low of $642.00 and a 1-year high of $1,211.20. The company has a market capitalization of $75.02 billion, a PE ratio of 17.94, a PEG ratio of 2.34 and a beta of 0.08. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.73 and a quick ratio of 3.95.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last posted its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $11.21 by $0.86. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The company had revenue of $3.79 billion for the quarter, compared to the consensus estimate of $3.76 billion. During the same period last year, the firm posted $11.86 EPS. The company's revenue for the quarter was up 10.3% on a year-over-year basis. On average, equities research analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Thursday, March 20th. Shareholders of record on Thursday, February 20th will be paid a $0.88 dividend. The ex-dividend date of this dividend is Thursday, February 20th. This represents a $3.52 dividend on an annualized basis and a yield of 0.51%. Regeneron Pharmaceuticals's payout ratio is currently 2.30%.

Analyst Ratings Changes

Several analysts have commented on the stock. StockNews.com cut shares of Regeneron Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research note on Monday, November 4th. UBS Group lowered Regeneron Pharmaceuticals from a "buy" rating to a "neutral" rating and dropped their target price for the company from $1,130.00 to $738.00 in a research note on Thursday, January 16th. Piper Sandler decreased their price target on Regeneron Pharmaceuticals from $1,195.00 to $1,013.00 and set an "overweight" rating on the stock in a research note on Monday, January 27th. Bank of America restated an "underperform" rating and issued a $565.00 target price on shares of Regeneron Pharmaceuticals in a report on Tuesday, December 10th. Finally, Citigroup cut their price target on shares of Regeneron Pharmaceuticals from $795.00 to $750.00 and set a "neutral" rating on the stock in a research note on Tuesday, January 28th. One research analyst has rated the stock with a sell rating, six have assigned a hold rating, seventeen have issued a buy rating and two have issued a strong buy rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $973.13.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.